Reproductive toxicology profile of emtricitabine in mice and rabbits

Reproductive Toxicology

Volumn 17, Issue 1, 2003, Pages 95-108

  Szczech, George M ^a   Wang, Laurene H ^a   Walsh, John P ^a   Rousseau, Franck S ^a  

^a Triangle Pharmaceuticals   (United States)

Author keywords

Coviracil ; Developmental toxicology; Emtricitabine; Fertility; FTC; Mouse; Rabbit; Reproductive toxicology

Indexed keywords

EMTRICITABINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; EMBRYO DEVELOPMENT; FEMALE; FERTILITY; FETUS MALFORMATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUSE; NONHUMAN; POSTNATAL DEVELOPMENT; PRENATAL DEVELOPMENT; PROGENY; REPRODUCTION; REPRODUCTIVE TOXICITY; SPERMATOZOON COUNT;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BEHAVIOR, ANIMAL; BODY WEIGHT; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; FERTILITY; MALE; MICE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RABBITS; REPRODUCTION; SPERM COUNT;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 0037221879     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(02)00098-9     Document Type: Article

References (33)

1. AIDS Epidemic Update, UNAIDS/WHO, E-mail: unaids@unaids.org, 2000.
2. Hirsche S, Brun-Vézinet F, S'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA 2000;283:2417-26.
3. Miller RK. Anti-HIV therapy during pregnancy: risk-benefit ratio. Teratology 2000;62:288-90.
4. Blanchard S, Tardieu M, Rustin P, Slama A, Barret B, Firton G, et al. Persistent mitochondrial dysfunction and peri-natal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-9.
5. The Peri-natal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J AIDS 2000;25:261-8.
6. Grizzle TB, Delehanty J, Wang LH, Rousseau FS, Szczech GM. Pre-clinical safety evaluation of emtricitabine (Coviracil®) [Abstract WePa4058]. In: Proceedings of the XIII International AIDS conference program, 9-14 July 2000; Durban, South Africa.
7. Title 21, United States Code of Federal Regulations, Part 58, Good Laboratory Practice for Non-clinical Studies (Effective 6-20-79).
8. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Toxicity to male fertility: an addendum to the ICH Tripartite Guideline on Detection of toxicity to reproduction for medicinal products, 1995. Available at 〈http://www.ifpma.org/ich5.html〉.
9. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Detection of toxicity to reproduction for medicinal products, 1993. Available at 〈http://www.ifpma.org/ich5.html〉.
10. International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use. Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies, 1994. Available at 〈http://www.ifpma.org/ich5.html〉.
11. Cox DR. Regression methods and life tables (with discussion). J Royal Statistical Soc, Series B 1972;34:187-220.
12. Haseman JK, Kupper LL. Analysis of dichotomous data from certain toxicological experiments. Biometrics 1979;35:281-93.
13. Laird MN, Ware JH. Random effects models for longitudinal data. Biometrics 1982;38:963-74.
14. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Institute, Inc; 1996.
15. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955;50:1096-121.
16. Dunnett CW. New tables for multiple comparisons with a control. Biometrics 1964;20:482-91.
17. Triangle Report 4436. Study of fertility and early embryonic development of emtricitabine administered by gavage to CD-1 mice (Segment I). Study Director S. Tyl, Research Triangle Institute, Research Triangle Park, NC.
18. Salewski VE. Färbemethode zum makroskopischen nachweis von implantationstellen am uterus der ratte. Naunyn-Schmiedebergs Arch Exp Pathol Pharmakol 1964;247:367.
19. Triangle Report 4115. A study of the effects of emtricitabine on embryo/fetal development in mice (Segment II). Study Director J. Schardien, WIL Research Laboratories, Inc., Ashland, OH.
20. Wilson JG. Embryological considerations in teratology. In: Wilson JG, Warkany J, editors. Teratology: principles and techniques. Chicago: The University of Chicago Press; 1965, p. 251-77.
21. Dawson AB. A note on the staining of the skeleton of cleared specimens with Alizarin Red S. Stain Technol 1926;1:123-4.
22. Triangle Report 9318. A study of the effects of emtricitabine on embryo/fetal development in rabbits (Segment II). Study Director D. Stump, WIL Research Laboratories, Inc., Ashland, OH.
23. Stuckhardt JL, Poppe SM. Fresh visceral examination of rat and rabbit fetuses used in teratogenicity testing. Teratogenesis, Carcinogenesis, and Mutagenesis 1984;4:181-8.
24. Staples RE. Detection of visceral alterations in mammalian fetuses. Teratology 1974;9:37-8.
25. Triangle Report 5063. Pre- and post-natal development study in CD-1 mice given emtricitabine by gavage (Segment III). Study Director S. Tyl, Research Triangle Institute, Research Triangle Park, NC.
26. Morris RGM. Spatial localization does not require the presence of local cues. Leaming and Motivation 1981;12:239-60.
27. Khera KS. Chemically induced alterations in maternal homeostasis and histology of conceptus: their etiologic significance in rat fetal anomalies. Teratology 1991;44:259-97.
28. Khera KS. Maternal toxicity: a possible etiological factor in embryo-fetal deaths and fetal malformations of rodent-rabbit species. Teratology 1985;31:129-53.
29. Daston GP. Relationships between maternal and developmental toxicity. In: Kimmel C, Buelke-Sam J, editors. Developmental Toxicology, 2nd ed. New York: Raven Press, 1994, p. 189-212.
30. Frick LW, Lambe CU, St John L, Taylor LC, Nelson DJ. Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2′R,5′S)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. Antimicrob Agents Chemother 1994;38:2722-9.
31. Greene JA, Ayers KM, Tucker Jr. WE, de Miranda P. Non-clinical toxicology studies with zidovudine: reproductive toxicity studies in rats and rabbits. Fundam Appl Toxicol 1996;32:140-7.
32. Schilling BE, Nelson DR, Proctor JE, Diamond SS, Kaul S, Hawkins C. The non-clinical toxicologic profile of stavudine. Curr Ther Res 1995;56:201-18.
33. Physicians Desk Reference. 55th ed. Montvale, NJ: Medical Economics Co., Inc.; 2001, p. 1374-82.